Symlin And How To Market On Montel Williams

During the PhRMA annual meeting March 18, Amylin CEO Ginger Graham took talk show host Montel William's advice to be proactive in working with him: she volunteered to come on his program, "The Montel Williams Show," to talk about the diabetes agent Symlin (pramlintide), which was approved by FDA two days earlier. In the following exchange, transcribed by "The Pink Sheet," Graham and Williams discuss ways to present a balanced message about a new drug. As of March 22, Amylin said it had not yet made any firm plans with Williams to do a program.

More from Archive

More from Pink Sheet